A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter: 9 X users
patent: 2 patents

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 72 Dimensions

Readers on

mendeley: 106 Mendeley

Summary X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 16 X posts from 9 X users, with an upper bound of 72,864 followers.

#JITC: A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) https://t.co/tViGSlSaTA

30 May 2019

Reply Repost Favourite

RT @ChristianRolfo: #OncoAlert https://t.co/Rwrxx2MYId

14 May 2019

Reply Repost Favourite

RT @sitcancer: #JITC: A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients wi…

13 May 2019

Reply Repost Favourite

RT @ChristianRolfo: #OncoAlert https://t.co/Rwrxx2MYId

13 May 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 12 additional X posts.